Sermorelin
Also known as: GHRH(1-29)NH2, GRF 1-29
Quick summary
The first 29 amino acids of growth hormone–releasing hormone, the shortest piece that keeps full activity. Research focus: pituitary GH secretion, GH pulsatility and somatostatin interplay. This page leads with SRP's low-and-slow starting dose.
Amino acid sequence (one-letter code): YADAIFTNSYRKVLGQLSARKLLQDIMSR
Overview
The first 29 amino acids of growth hormone–releasing hormone, the shortest piece that keeps full activity. It is used to study how the pituitary releases growth hormone.
Looking for research material? Simple Research Peptides lists Sermorelin (10 mg Vial) for laboratory research use.
Mechanism
The first 29 amino acids of native GHRH, the shortest fully active fragment. It stimulates pituitary GHRH receptors and is short-acting.
Research areas
- pituitary GH secretion
- GH pulsatility
- somatostatin interplay
Storage & reconstitution
Typically supplied as a lyophilized powder; keep sealed vials cold (refrigerated short term, frozen for long-term holding) and away from light. Laboratories commonly reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, and keep the solution refrigerated, using it within a few weeks.
Recommended starting dose (low and slow)
| Starting dose | Example starts at 100 mcg nightly for weeks 1-2; ranges start at 200 mcg. |
|---|---|
| Frequency | Reported: 100-300 mcg subcutaneous once daily. |
| Reconstitution | 1-2 mL bacteriostatic water per vial; avoid freeze-thaw cycles and aliquot if storing. |
~100-300 mcg SC daily (half-life 10-20 min).
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | 500 mcg per night (agree; tops at 300 mcg, reference at 0.5 mg). Existing frequency (100-300 mcg daily) is lower. |
|---|---|
| Step-up schedules reported | Example nightly: 100 mcg weeks 1-2, 200 mcg weeks 3-4, 300 mcg weeks 5-8, then 400-500 mcg from week 9 if needed. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Very short, roughly 10 to 20 minutes.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; IGF-1, fasting glucose and HbA1c.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is Sermorelin studied for?
In research it is studied for pituitary GH secretion, GH pulsatility and somatostatin interplay. The first 29 amino acids of native GHRH, the shortest fully active fragment.
How is Sermorelin given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026